Author:
Nomura Kotaro,Aokage Keiju,Kaminuma Yasunori,Nakai Tokiko,Wakabayashi Masashi,Ikeno Takashi,Koike Yutaro,Taki Tetsuro,Miyoshi Tomohiro,Tane Kenta,Samejima Joji,Ishii Genichiro,Tsuboi Masahiro
Funder
National Cancer Center Research and Development Funds
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Ferlay J EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr/today. Accessed 24, August 2022
2. Ettinger DS, Wood DE, Aisner DL (2022) NCCN Guidelines Version 3.2022 Non-Small Cell Lung Cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 24 August 2022
3. Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559. https://doi.org/10.1200/jco.2007.13.9030
4. Hung JJ, Yeh YC, Jeng WJ et al (2014) Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol 32(22):2357–2364. https://doi.org/10.1200/jco.2013.50.1049
5. Travis WD, Brambilla E, Rami-Porta R et al (2008) Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol 3(12):1384–1390. https://doi.org/10.1097/JTO.0b013e31818e0d9f